Ibogaine is a Schedule I controlled substance under federal law in the United States, meaning it is illegal to manufacture, distribute, or possess without a DEA research registration. Last verified: April 2026.

Current Legal Status

Ibogaine has been classified as a Schedule I substance under the Controlled Substances Act (CSA) since 1970. Under 21 U.S.C. § 812, Schedule I substances are defined as having no currently accepted medical use, a high potential for abuse, and a lack of accepted safety for use under medical supervision. This classification applies to ibogaine hydrochloride and all ibogaine-containing preparations.

The practical consequences of this scheduling are significant:

  • Possession, distribution, and manufacture of ibogaine are federal criminal offenses.
  • No licensed U.S. physician can legally prescribe ibogaine outside of an approved research context.
  • Clinical use is restricted to DEA-registered researchers operating under an approved Investigational New Drug (IND) application from the FDA.
  • Ibogaine-assisted treatment cannot be legally administered at U.S. clinics under current federal law.

Federal Research Pathway

Researchers seeking to study ibogaine in the U.S. must obtain both a DEA Schedule I researcher registration and an FDA IND application. This pathway is narrow and does not create any general medical or therapeutic exception. A small number of academic and clinical research programs have operated under this framework, primarily studying ibogaine's potential for treating opioid use disorder.

No Religious or Personal Use Exemptions

Unlike some controlled substances — most notably peyote, which carries a narrow exemption for the Native American Church under 42 U.S.C. § 1996a — there are currently no recognized religious carve-outs or personal use exemptions for ibogaine under federal law. Courts have not established a protected religious use category for ibogaine, and the DEA has not granted any such exemption.

State-Level Variation

While ibogaine remains federally illegal, a small number of states have taken legislative steps related to psychedelic-assisted therapy research, and ibogaine-specific legislation has emerged in at least one state. It is important to note that state law cannot override federal scheduling — state-level actions create research frameworks or funding mechanisms, but do not legalize ibogaine possession or administration under federal law.

Important: No U.S. state has legalized ibogaine for personal use or therapeutic administration outside of a federally approved research context. Any facility advertising ibogaine treatment inside the United States is operating outside both federal and state law.

Treatment Centers

There are currently no legally operating ibogaine treatment clinics inside the United States. Because ibogaine is a federal Schedule I substance, therapeutic administration at a U.S.-based clinic is not legally permissible. Facilities that advertise ibogaine treatment within U.S. borders are doing so in violation of federal law, and patients using such services face potential legal exposure in addition to unregulated medical risk.

Legal ibogaine treatment options accessible to U.S. residents are located in other countries — most commonly Mexico, which has no federal scheduling of ibogaine, as well as Canada, Portugal, the Netherlands, and several other jurisdictions where ibogaine therapy operates legally or in a regulatory gray area.

For a full directory of verified ibogaine treatment centers operating in legal jurisdictions, see our clinic directory.

How People Access Ibogaine in the United States

This section describes how access occurs factually and does not constitute a recommendation or endorsement of any activity that may violate applicable law.

Travel to Legal Jurisdictions

The most common route U.S. residents use to access ibogaine treatment is international travel to clinics in countries where ibogaine is legal or unscheduled. Mexico — particularly the Baja California region near the U.S. border — hosts a large concentration of ibogaine clinics that serve American patients. Traveling abroad for treatment is not itself a U.S. federal crime, though returning to the U.S. with ibogaine would be.

Participation in Clinical Trials

Individuals may be eligible to receive ibogaine in a controlled research setting through FDA-approved clinical trials registered with the DEA. ClinicalTrials.gov lists active and recruiting studies. Eligibility criteria are strict, and participation involves rigorous medical screening.

Underground and Unregulated Access

Some individuals access ibogaine through informal, unregulated channels within the United States. This carries serious legal risk (federal Schedule I possession charges) as well as substantial medical risk, since no licensed oversight, cardiac screening, or emergency medical infrastructure is present in underground settings. Ibogaine carries a known risk of fatal cardiac arrhythmia, and deaths have occurred in unsupervised contexts.

Recent Legal Developments

Texas SB 2640 (2025)

In 2025, the Texas Legislature passed Senate Bill 2640, which established a framework for clinical research funding related to certain psychedelic substances, including ibogaine, as potential treatments for conditions such as post-traumatic stress disorder and opioid use disorder. The bill was directed in part at supporting research relevant to veteran mental health.

It is important to understand what SB 2640 does and does not do:

  • It creates a state-level research fund and framework — it does not legalize ibogaine in Texas.
  • Any research conducted under this framework must still comply with federal DEA and FDA requirements for Schedule I research.
  • The implementation status of this legislation — including whether funding has been appropriated and whether any research programs are actively operating under it — remains uncertain as of April 2026. Prospective participants or researchers should verify current program status directly with Texas state health authorities.
  • SB 2640 does not create a therapeutic exception, personal use exemption, or licensed clinic framework in Texas.

Federal Legislative Proposals

Several federal bills related to psychedelic research have been introduced in recent congressional sessions, including proposals to ease research restrictions on Schedule I substances and to fund studies into ibogaine's potential for treating opioid use disorder and PTSD among veterans. None of these proposals have resulted in changes to ibogaine's Schedule I status. The legislative landscape shifts regularly, and the current status of any specific federal bill should be verified through Congress.gov.

FDA Breakthrough Therapy Designation Context

While no ibogaine product currently holds FDA Breakthrough Therapy Designation, the FDA has granted such designations to other psychedelic-adjacent compounds in recent years, signaling some openness to accelerated review pathways. This does not affect ibogaine's scheduling but reflects a broader regulatory environment in which psychedelic research is receiving increased institutional attention.

Note: Legislative activity in the psychedelic research space is moving quickly. Always verify the current status of any specific bill or program through official government sources before making decisions based on proposed legislation.

Risks of Seeking Treatment in the United States

Legal Risks

Possessing ibogaine in the United States is a federal felony under the CSA. Penalties can include significant prison terms and fines. Operators of underground treatment sessions face additional charges including distribution and conspiracy. Law enforcement has investigated and prosecuted ibogaine-related cases, though enforcement has historically been inconsistent.

Medical Risks in Unregulated Settings

Ibogaine carries a clinically significant risk of fatal cardiac events, particularly QT interval prolongation and ventricular arrhythmias. In legal treatment settings abroad, reputable clinics typically require an electrocardiogram (ECG), cardiac clearance, and on-site medical personnel. Underground U.S. sessions typically lack these safeguards entirely.

Additional medical risks in unregulated settings include:

  • No drug interaction screening (ibogaine has dangerous interactions with opioids, stimulants, and many psychiatric medications).
  • No ability to call emergency services without exposing participants to criminal liability.
  • Unverified substance purity and dosing.
  • No post-session integration support or medical follow-up.

No Consumer Protections

Because ibogaine treatment has no legal framework in the U.S., there are no licensing requirements, no minimum standards of care, no malpractice recourse, and no regulatory oversight for anyone offering ibogaine services domestically. Individuals who are harmed in an underground session have no meaningful legal recourse.

Frequently Asked Questions

No. Ibogaine is a Schedule I controlled substance under the federal Controlled Substances Act, which applies in all 50 states, U.S. territories, and the District of Columbia. No state has created a legal framework that permits the possession, administration, or distribution of ibogaine outside of a federally approved research context. State-level legislation such as Texas SB 2640 creates research funding mechanisms but does not legalize ibogaine use.
No. U.S. physicians cannot prescribe Schedule I substances. The only legal avenue for a physician to administer ibogaine is as part of a DEA-registered research study operating under an FDA Investigational New Drug (IND) application. This is a research context, not a standard therapeutic prescription relationship. Outside of approved clinical trials, any physician administering ibogaine would be violating federal law and risking their medical license.
Traveling from the U.S. to Mexico for ibogaine treatment is not itself a U.S. federal crime. However, returning to the United States with ibogaine in your possession would be a federal import and possession offense under the CSA. U.S. residents should also be aware that state laws may vary, and that international travel for drug-related purposes can carry additional legal complexity. This is not legal advice — consult a licensed attorney before making decisions.
Texas SB 2640, passed in 2025, established a state-level clinical research fund and framework intended to support studies into ibogaine and other substances as potential treatments for conditions including PTSD and opioid use disorder, with a focus on veteran populations. It did not legalize ibogaine in Texas, did not create a licensed clinic framework, and did not override federal scheduling. Any research conducted under it must still comply with DEA and FDA federal requirements for Schedule I research. The specific implementation status — including whether funding has been allocated and whether active research programs are operating — was uncertain as of April 2026. Contact the Texas Health and Human Services Commission or consult official state sources for current program details.
No. There are no legally operating ibogaine treatment clinics inside the United States. Because ibogaine is a federal Schedule I substance, therapeutic administration cannot legally occur at a U.S. clinic. Any domestic facility advertising ibogaine treatment is operating outside federal law. Legal ibogaine treatment options for U.S. residents are located in other countries, including Mexico, Canada, Portugal, and the Netherlands. See our clinic directory for verified international options.
Rescheduling is legally possible. The DEA can reschedule a substance through its own initiative or in response to a petition, following a review process that includes an FDA medical and scientific evaluation. Congress can also reclassify substances through legislation. Growing research into ibogaine's potential for treating opioid use disorder and PTSD has prompted increased political interest, including from veteran advocacy groups. However, as of April 2026, no rescheduling action is underway, and ibogaine remains Schedule I. Any claims that rescheduling is imminent should be verified against current DEA and FDA official communications.
Both ibogaine and psilocybin are currently Schedule I controlled substances under federal law. They are chemically distinct compounds with different pharmacological profiles, risk profiles, and legal trajectories. Oregon passed Measure 109 in 2020 to create a licensed psilocybin services framework — this law applies only to psilocybin and has no relevance to ibogaine's legal status. Colorado similarly passed Proposition 122 relating to psilocybin and certain other substances, but ibogaine was not included. State-level psilocybin reforms do not affect ibogaine's Schedule I status in any jurisdiction.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.